High_JJ
frequency_NN
of_IN
germ-line_JJ
BRCA2_NN
mutations_NNS
among_IN
Hungarian_JJ
male_JJ
breast_NN
cancer_NN
patients_NNS
without_IN
family_NN
history_NN
._.

To_TO
determine_VB
the_DT
contribution_NN
of_IN
BRCA1_NN
and_CC
BRCA2_NN
mutations_NNS
to_TO
the_DT
pathogenesis_NN
of_IN
male_JJ
breast_NN
cancer_NN
in_IN
Hungary_NNP
,_,
the_DT
country_NN
with_IN
the_DT
highest_JJS
male_JJ
breast_NN
cancer_NN
mortality_NN
rates_NNS
in_IN
continental_JJ
Europe_NN
,_,
a_DT
series_NN
of_IN
18_CD
male_JJ
breast_NN
cancer_NN
patients_NNS
and_CC
three_CD
patients_NNS
with_IN
gynecomastia_NN
was_VBD
analyzed_VBN
for_IN
germ-line_NN
mutations_NNS
in_IN
both_CC
BRCA1_NN
and_CC
BRCA2_NN
._.

Although_IN
no_DT
germ-line_NN
BRCA1_NN
mutation_NN
was_VBD
observed_VBN
,_,
6_CD
of_IN
the_DT
18_CD
male_JJ
breast_NN
cancer_NN
cases_NNS
-LRB-_-LRB-
33_CD
%_NN
-RRB-_-RRB-
carried_VBD
truncating_JJ
mutations_NNS
in_IN
the_DT
BRCA2_NN
gene_NN
._.

Unexpectedly_RB
,_,
none_NN
of_IN
them_PRP
reported_VBD
a_DT
family_NN
history_NN
for_IN
breast\/ovarian_JJ
cancer_NN
._.

Four_CD
of_IN
six_CD
truncating_JJ
mutations_NNS
were_VBD
novel_JJ
,_,
and_CC
two_CD
mutations_NNS
were_VBD
recurrent_JJ
._.

Four_CD
patients_NNS
-LRB-_-LRB-
22_CD
%_NN
-RRB-_-RRB-
had_VBD
a_DT
family_NN
history_NN
of_IN
breast\/ovarian_JJ
cancer_NN
in_IN
at_IN
least_JJS
one_CD
first_RB
-_JJ
or_CC
second-degree_JJ
relative_JJ
;_:
however_RB
,_,
no_DT
BRCA2_NN
mutation_NN
was_VBD
identified_VBN
among_IN
them_PRP
._.

No_DT
mutation_NN
was_VBD
identified_VBN
in_IN
either_DT
of_IN
the_DT
genes_NNS
in_IN
the_DT
gynecomastias_NNS
._.

These_DT
results_NNS
provide_VBP
evidence_NN
for_IN
a_DT
strong_JJ
genetic_JJ
component_NN
of_IN
male_JJ
breast_NN
cancer_NN
in_IN
Hungary_NNP
._.

